Chronic neuroinflammation is a key pathological feature of neuropathic pain. The ketogenic diet (KD) has demonstrated potential to reduce neuronal excitability and alleviate inflammation in epilepsy, yet its effects and precise mechanisms in neuropathic pain remain elusive. We first observed that β-hydroxybutyrate (BHB), a key metabolite induced by KD, was reduced in mice following neuropathic pain induced by chronic constriction injury (CCI). Subsequently, we demonstrated that KD effectively alleviated CCI-induced thermal hyperalgesia and mechanical allodynia, while mitigating neuroinflammation through reduced microglial activation and pro-inflammatory cytokine levels. BHB reduced reactive oxygen species (ROS) production, which coincided with enhanced mitochondrial membrane potential in microglia, thereby attenuating microglia-mediated inflammatory responses. Both in vivo and in vitro experiments revealed KD-induced upregulation of uncoupling protein 2 (UCP2), sirtuin 3 (SIRT3) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) in the spinal dorsal horn. Importantly, SIRT3 deficiency abolished KD's protective effects against neuropathic pain and reduced BHB levels, potentially attributable to diminished expression of hepatic ketone body synthases and spinal ketone body-utilizing enzymes. These findings highlight SIRT3 as a promising therapeutic target for neuropathic pain within the ketogenic diet paradigm, providing a foundation for novel therapeutic strategies.
Depression is a highly heterogeneous psychiatric disorder with its pathogenesis increasingly linked to dysregulated neuroinflammation. Microglia, as the resident immune cells of the central nervous system (CNS), play a pivotal role in the initiation and progression of the neuroinflammation and the pathophysiology of depression. These cells exhibit a dual role in pro- and anti-inflammatory processes, dynamically regulating immune responses through immunometabolic reprogramming in response to environmental cues. This review elaborates how metabolic remodeling in microglia, particularly within glucose, lipid, and amino acid pathways, drives their polarization toward a pro-inflammatory phenotype. This shift promotes depression pathogenesis via the release of inflammatory factors, disruption of synaptic plasticity, and mediation of neurotoxicity. We further discuss the impact of existing antidepressants on cellular metabolism and highlight the promise and challenges of targeting specific microglial metabolic pathways as a novel therapeutic strategy. This synthesis provides new insights into the immunometabolic mechanisms of depression and outlines directions for developing targeted treatments.
Background: The global prevalence of VCI has increased steadily in recent years, but diagnostic biomarkers for VCI in patients with non-disabling ischemic cerebrovascular incidents (NICE) remain indefinite. The primary objective of this research was to investigate the relationship between peripheral serological markers, white matter damage, and cognitive function in individuals with NICE. Methods: We collected clinical data, demographic information, and medical history from 257 patients with NICE. Using the MoCA upon admission, patients were categorized into either normal cognitive function (NCF) or VCI groups. Furthermore, they were classified as having mild white matter hyperintensity (mWMH) or severe WMH based on Fazekas scores. We then compared the levels of serological markers between the cognitive function groups and the WMH groups. Results: Among 257 patients with NICE, 165 were male and 92 were female. Lymphocyte count (OR = 0.448, P < 0.001) and LDL-C/HDL-C (OR = 0.725, P = 0.028) were protective factors for cognitive function in patients with NICE. The sWMH group had a higher age and inflammation markers but a lower MoCA score, and lymphocyte count than the mWMH group. In the mWMH group, lymphocyte count (AUC = 0.765, P < 0.001) and LDL-C/HDL-C (AUC = 0.740, P < 0.001) had an acceptable diagnostic value for the diagnosis of VCI. In the sWMH group, no significant differences were found in serological markers between the NCF and VCI groups. Conclusion: Lymphocyte count, LDL-C/HDL-C were independent protective factors for cognitive function in patients with NICE; they can be used as potential biological markers to distinguish VCI in patients with NICE and are applicable to subgroups of patients with mWMH.
Cortical laminar necrosis (CLN) is a rare form of ischemic necrosis characterized by laminar damage primarily affecting the third to fifth cortical layers. CLN typically follows cerebral infarction but can also arise from various conditions. However, research on CLN is scarce, and predictive models have not yet been established, limiting clinical guidance. We aimed to analyze the risk factors for poor prognosis in patients with CLN after cerebral infarction and to construct a visual nomogram model with early predictive value. This retrospective study included 80 patients admitted to our hospital between January 2019 and December 2024. The modified Rankin Scale (mRS) was used to assess functional outcomes at 90 days after symptom onset. Clinical and imaging data were compared between patients with favorable outcomes (mRS 0–2, n = 56) and those with poor outcomes (mRS 3–6, n = 24). Independent risk factors for poor outcomes were identified through multivariable logistic regression analysis. R software was used to generate a nomogram; the model was evaluated and internally validated. Compared with the favorable outcome group, the poor outcome group had significantly higher age, admission National Institutes of Health Stroke Scale (NIHSS) score, C-reactive protein level, severity of white matter hyperintensity (WMH), and the degree of anterior cerebral artery (ACA) stenosis. Body mass index and albumin levels were significantly lower in the poor outcome than in the favorable outcome group (all P < .05). Admission NIHSS score (odds ratio [OR] = 1.317; 95% confidence interval [CI] 1.097–1.669; P = .008), WMH severity (OR = 5.273; 95% CI 1.181–28.519; P = .037), and degree of ACA stenosis (OR = 7.223; 95% CI 1.631–38.985; P = .013) were independent risk factors for poor outcome of CLN. The C-index (0.852) and calibration curve indicated that the nomogram model had high discriminative ability and accuracy. The area under the receiver operating characteristic curve was 0.867 (95% CI 0.811–0.906). Admission NIHSS score, WMH severity, and degree of ACA stenosis were independently and significantly associated with the prognosis of CLN. The nomogram model developed in this study exhibits strong predictive capability and good discriminative ability and accuracy, enhancing prognosis prediction in patients with CLN following cerebral infarction.